Condition: Solid Tumor · MET Alteration · Sponsor: Pierre Fabre Medicament
The goal of this clinical trial is to investigate the safety, the activity of VERT-002 (PFL-002), and the optimal safe dose to be used, in participants with solid tumors including non-small cell lung cancer.
This description comes directly from the study's public registry record.
Medical Officer · +33 684 66 43 48 · yuhua.wang@pierre-fabre.com
Always discuss trial participation with your own doctor first.
| Georgetown Lombardi Comprehensive Cancer Center | Washington D.C., District of Columbia, United States | Recruiting |
| Gabrail Cancer Research Center | Canton, Ohio, United States | Recruiting |
| Sarah Cannon Research Institute Oncology Partners | Nashville, Tennessee, United States | Recruiting |
| Institut Jules Bordet | Anderlecht, Belgium | Recruiting |
| APHP de Marseille - Hôpital Nord | Marseille, France | Recruiting |
| Institut de Cancerologie de Ouest (ICO) - Saint-Herblain | Saint-Herblain, France | Recruiting |
| Institut Universitaire du Cancer de Toulouse - Oncopole | Toulouse, France | Recruiting |
| Gustave Roussy | Villejuif, France | Recruiting |
| Universitaet zu Koeln - Centrum fuer Integrierte Onkologie (CIO) | Cologne, Germany | Recruiting |
| Universitätsklinikum Carl Gustav Carus Dresden | Dresden, Germany | Recruiting |
| Azienda Ospedaliero - Universitaria San Luigi Gonzaga | Orbassano, Italy | Recruiting |
| Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis | Amsterdam, Netherlands | Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06669117